Opinion
Video
Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis
Key Takeaways
- Belimumab and voclosporin have unique mechanisms of action, impacting their efficacy and safety profiles in lupus nephritis treatment.
- Payers consider clinical outcomes, cost, and value when evaluating belimumab and voclosporin for lupus nephritis management.
Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost-effectiveness in LN management.
Video Player is loading.
What is your perspective on the differences between the efficacy and safety profiles of belimumab and voclosporin in the treatment of lupus nephritis (LN)? (Dr. Larranaga and Dr. Wells)
How are payers evaluating the value of belimumab and voclosporin in the management of LN? (Dr. Wigginton)
- What does cost-effectiveness look like in LN management?
Related Videos
Building Better Collaboration: Reducing Care Delays in Managing mCRC
Best Practices for Overcoming mCRC Prior Authorization Barriers
Introduction to IgA Nephropathy
Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025
Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime
Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease
Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies
CGM Coverage and Access
Minimizing Antibiotic Resistance Development in Uncomplicated UTIs
Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas
Related Content
